The Daily

Central European Summer Time starts on Sunday, 29 March 2026: clocks in Italy (and much of Europe) move forward by one hour at 02:00 CET. The obvious impact is sleep — you lose an hour — but the practical travel impact is worse: early-morning trains, airport transfers and hotel check-ins on that weekend get messy if you’re not already in “summer time mode”. There’s also a political wrinkle: the EU has had a proposal on the table since 2018 to end the twice-yearly change, but the decision remains on hold.

A new Tuscany stay to pin for early summer: Chapter Chianti is slated to open in June 2026 in the Chianti region, about 45 minutes from Florence. The property is set in a restored 16th-century medieval village on 99+ acres, with three restaurants/bars, a 500 m² spa, and a private villa (“The Mansion”). Standard doubles are listed from €400 per night (B&B), which puts it firmly in “special trip” territory — but it’s exactly the kind of shoulder-season Italy that actually feels like a holiday.

Reuters reports that the Financial Times expects OpenAI to nearly double headcount from about 4,500 to 8,000 by the end of 2026. The key detail: hiring is aimed across product, engineering, research and sales, plus “technical ambassadorship” roles to help companies use OpenAI tools more effectively. That’s a sign the next bottleneck is less “train bigger models” and more “make adoption boring and reliable”. Context: OpenAI’s last funding round was reported at $110B (valuation cited by Reuters: $840B), and the company has been in “code red” mode since late 2025.

Ars Technica says Amazon is developing a new smartphone more than a decade after the Fire Phone, citing a Reuters report. The device is reportedly codenamed Transformer and is meant to pull users deeper into Amazon’s ecosystem — shopping, Prime Video/Music, and especially AI. One provocative idea: use AI features instead of a traditional app store, taking inspiration from the Light Phone. If Amazon ships this, it’s an explicit bet that “assistant-native” UX can finally become a hardware wedge.

CNBC’s write-up of the OpenAI headcount plan is short, but it’s a useful indicator: “who’s hiring” in AI is now treated like a market-moving metric. When a company is said to be going to 8,000 people, it changes expectations around support, enterprise sales muscle, and how fast new product lines can be staffed. It also quietly raises the stakes for competitors: the “talent war” isn’t just research scientists anymore — it’s the unglamorous operators who make systems stable at scale.

Nature reports on immune cells engineered to detect extremely low levels of a target antigen — and in mouse models they eliminated kidney, ovarian and pancreatic tumors, which have historically been a graveyard for conventional CAR‑T. The paper points to a broader pattern: solid tumors aren’t just “hard” because of trafficking, they’re hard because targets are sparse and heterogeneous. The work cites results published in Science (2026) and suggests that sensitivity thresholds might be as important as the target choice itself. If this translates, it would reopen the conversation around CAR‑T for solid malignancies — with a different engineering problem at the center.

A Blood meta-analysis compared CAR‑T therapy with CD20×CD3 bispecific antibodies in relapsed/refractory DLBCL after third line or later. Across 16 studies with 1,347 patients, the pooled complete response rate was 0.36 for bispecifics versus 0.51 for CAR‑T (P < .01). The practical implication isn’t “bispecifics are worse” — it’s that sequencing and patient selection matter: CAR‑T still looks like the deepest punch, while bispecifics may win on access and logistics. The next fight is going to be: who gets which modality first, and why.

Reuters reports the US is engaging drugmakers to lock former President Trump’s “Most Favored Nation” (MFN) pricing plan into statute — not just executive policy. According to Stat (cited by Reuters), the administration is pursuing agreements with 16 manufacturers and asking companies to drop prices to avoid being targeted. A blunt detail from the conference: patients can pay up to three times what foreigners pay for the same drugs, according to the report. The implication is obvious: even before any law passes, the negotiation posture alone can shift US pricing strategy.

Fierce Biotech reports Gilead has returned rights to Assembly’s HBV candidate ABI‑4334, putting Assembly back in sole control while it looks for a new partner. The backdrop is a big deal: Gilead paid $100M upfront in October 2023 for opt-in rights on Assembly’s pipeline (a 12‑year pact), with potential milestones of $330M. ABI‑4334 entered a phase 1b study in 2024, but Gilead “declined to exercise or defer its option”. The practical lesson: options derisk the buyer — and can leave the biotech scrambling when priorities change.

BioSpace reports AstraZeneca plans a commercial cell therapy manufacturing base and a dedicated innovation center in Shanghai. The stated ambition is end-to-end capability — from early work to commercial production — to support launches of autologous CAR‑T therapies in China and broader Asian markets. The strategic point is timing: cell therapy supply chains are fragile even in the US/EU; building local capacity is as much about geopolitics and resilience as it is about science.

The AP recap is a clean snapshot of late-season stress basketball: Los Angeles 138, Dallas 131 (OT). Darius Garland posted a season-high 41 points and 11 assists; Kawhi Leonard added 34 and hit a tying bucket with 19 seconds left in regulation. Dallas’ home losing streak is now 11 games — their longest in 32 years — and it’s happening in exactly the part of the calendar where teams either stabilize or spiral. For the Clippers, ending a four-game skid matters almost as much as the standings math.

HoopsHype reports that an MRI on Anthony Edwards showed right knee inflammation, with a re-evaluation timeline of 1–2 weeks. It’s the classic “not a structural tear, but not nothing” scenario — and at this point of the season, even short absences can swing seeding. Watch how Minnesota manages minutes and contact load when he returns; the risk is less the current inflammation and more the compensation patterns that follow.

Kurzliste: „Salat“ (WUK, 25.03., 14:00), „Vom T‑Shirt zur Tasche“ (Technisches Museum, 22.03., 14:00), Familiendisco „Eltern Kind Bass“ (The Loft, 22.03., 15:00), Kalvarienbergfest/Ostermarkt (Hernals, ab 22.03., 11:00). Falter kuratiert diese Woche auffallend „hands-on“: Kleinkind-Performance mit Licht & Klang, Upcycling-Workshop (7–12 Jahre) und ein Club-Nachmittag mit Tanzfläche für 3–8-Jährige. Wenn ihr nur einen Fixpunkt setzt: der Technisches-Museum-Workshop ist die perfekte Mischung aus Basteln + „nebenbei was gelernt“.

Kurzliste: Familienführungen Botanischer Garten (Uni Wien, 1030; 22.–29.03.), Minigolf-Gratisrunde (DW, 1210; 25.03.), „Wildes Gemurmel in der Stadtbox“ (WIENXTRA-Spielebox, 1220; 30.–31.03.). Das Schöne an Kinderaktiv ist die Planbarkeit: viele Termine, klare Orte (inkl. Bezirke) und oft gratis oder sehr günstig. Für eine schnelle Nachmittags-Option ist Minigolf schwer zu schlagen — Low effort, high mood.

Kurzliste: Malma Art Café (1050; Kreativ-Café), Papa Duck (1060; Inari‑Tofu‑Taschen), Krawall Bar & Deli (1070; Sandwiches oben, Cocktails unten), Davy Art Space (1070; Kunst + Community, fix in der Lindengasse), HuHu Hotpot (1030; All‑you‑can‑eat Hotpot/Sushi). Der spannende Trend ist weniger „ein neues Lokal“ und mehr „hybride Räume“: Deli + Bar, Kunst + Kulinarik, Kaffee + Kreativstation. Wenn du einen Bezirk-Run machen willst: 1060/1070 sind gerade besonders dicht — ideal für einen kleinen Frühlingstestlauf.

Kurzliste: Marx Halle (1030) · Laufzeit 01.10.2025–03.05.2026 · heute (22.03.) 09:00–20:00 · Ticket €25. Falter beschreibt das Setup als „klassische Ausstellung“ in den ersten Räumen — und dann kippt es ins Immersive: VR‑Brillen, Orchesterklang, Meer, Glitzerstaub. Das ist natürlich nicht „Museum“ im traditionellen Sinn, aber als Sonntags-Block (vor allem bei schlechtem Wetter) funktioniert es genau deshalb: du bekommst Story, Bilder, und ein bisschen Adrenalin in einem.